David Berry is a general partner with venture capital firm Flagship Pioneering. In recent years, he has co-founded companies that are developing microbiome products for both human therapeutics and agricultural applications. He spoke with Xconomy during Biotech Week Boston in September about the promise of microbiome medicine and the challenges of developing a new class of drugs.

• Share on Facebook
• Share on Twitter
• LinkedIn
• Email
• Reprints

Trending on Xconomy

• Future of the Internet: What Scares Networking Pioneer Radia Perlman
• The Finalists for the 2019 Xconomy Awards Are …
• Amgen, Novartis BACE Inhibitor Joins List of Failed Alzheimer’s Drugs